Phase II trial of taxol given as a 3-hr infusion every 3 wk in relapsed non-Hodgkin's lymphoma (NHL) (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Phase II trial of taxol given as a 3-hr infusion every 3 wk in relapsed non-Hodgkin's lymphoma (NHL) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A1267 1994. Unique Identifier : AIDSLINE ICDB/94601263
Younes A; Sarris A; McLaughlin P; Romaguera J; Jendiroba D; Swan F; Rodriguez A; Hagemeister F; Moore D; Cabanillas F; UT M.D. Anderson Cancer Center, Houston, TX

Abstract: In August 1993, a Phase II trial of taxol given as a 3-hr infusion in relapsed NHL was initiated. Patients were eligible if they had pathologically documented relapsed low grade or intermediate grade lymphomas, a performance status of greater than or equal to 60% (Karnofsky), measurable disease, a platelet count of greater than or equal to 100,000/mm3 and an absolute neutrophil count of greater than or equal to 1000/mm3. Patients were excluded if they had HIV or CNS lymphoma, a history of arrhythmia, or active infection. After pre-medication with Decadron, Benadryl, and cimetidine, all patients received a starting dose of 200 mg/m2 of taxol infused over 3 hr in an outpatient setting. If no significant neutropenia (less than 500) or thrombocytopenia (less than 100,000) occurred the dose was escalated to 225 mg/m2 and 250 mg/m2 in the subsequent cycles. So far, 30 patients have been registered, of whom 19 are evaluable for response after 2 courses. Data are shown in a table. The 2 patients with diffuse large cell lymphoma who achieved CR with taxol received 2 prior chemotherapeutic regimens each. The treatment was very well tolerated and no patient experienced anaphylactic reaction or cardiac arrhythmias. The median neutrophil count nadir was 800/mm3 and the median platelet count nadir was 144,000/mm3. Our preliminary results indicate that taxol given at this dose and schedule is safe and active in relapsed NHL.

Keywords: Dose-Response Relationship, Drug Drug Administration Schedule Human Infusions, Intravenous Lymphoma, Non-Hodgkin's/*DRUG THERAPY/PATHOLOGY Neoplasm Recurrence, Local/*DRUG THERAPY/PATHOLOGY Neoplasm Staging Paclitaxel/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS ABSTRACT CLINICAL TRIAL, PHASE II CLINICAL TRIAL
940830
M9480781

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .